1789 TT

ScinoPharm Investor Conference

— 2023 06 08

ScinoPharm Taiwan

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation **is** ScinoPharm’s **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

Agenda

01 Company Overview

02 Business Update

03 Financial Performance



Company Overview

ScinoPharm at a Glance

- Est. 1997 in Taiwan with R&D/CGMP plants in Tainan and Changshu, China plus marketing forces in Tainan, Shanghai and Tokyo
- Specializes in providing R&D and CGMP manufacturing of APIs (cytotoxic/steroid) and injectable drug products
- 75 generic APIs in portfolio with 37 referred and approved ANDAs/NDAs*
  - 910 active DMFs worldwide with 67 US DMFs*
- 200+ contract projects with 11 approved/launched (9 NCEs) and 6 in phase 3 for NDA/MAA filing within 1-3 years*
- API plant certified by key international regulators - US FDA, EMA, EDQM, Australian TGA, Japanese PMDA, Korea KFDA, Mexico COFEPRIS and German Authority
- Injectable plant certified by US FDA and TFDA

*As of 2023/04/30



Business Updates

Optimize Generic API Portfolio

Generic API Portfolio



Optimize Generic API Portfolio

2023 Generic API Product Approval Plan

Type	Product	Region	Indication	Brand Marketer
Generic API	Bimatoprost	CN(✓)	Glaucoma	Allergan
Generic API	Cladribine	CN	Multiple sclerosis	Merck
Generic API	Galantamine HBr	CN	Alzheimer's disease	Janssen
Generic API	Azacitidine	EU	Myelodysplastic syndromes	Celgene

✓：Approved

As of 2023/04/30

Expand CDMO Business

CDMO Business Status



As of 2023/04/30

Expand CDMO Business

2023 CDMO Product Approval Plan

Type	Product	Region	Indication	Brand Marketer
CDMO API	Ganaxolone	EU	Genetic epilepsy	Marinus
CDMO API	Eflornithine	US/EU	FAP	Post-marketing Disclosure
CDMO API	Eflornithine	US/EU	Pediatric neuroblastoma	Post-marketing disclosure
Intermediate for CDMO API	Sotagliflozin	US(*)	Heart failure	Lexicon

* : Approved in May, 2023

Advancing to Injectables

In-House Drug Product Submission Status



*Responded to FDA CRL

Advancing to Injectables

Collaborative Projects for Drug Product

In-house Prefilled - syringe product

Signed marketing agreement with partner

Collaboration on 505(b)(2) for non-small cell lung cancer

Launched in US in Feb., 2022 by customer

Collaboration on ANDA for non-small cell lung cancer

Approved by US FDA in Aug., 2022 and by EMA in Dec., 2022

Collaboration on ANDA for multiple myeloma

Approved by US FDA in May, 2022

Contract Manufacturing of oncology Injectable

Partner submitted application to add SPT as a CMO site in 2023

China Market

- 4 CFDI on-site inspections completed in Changshu site to facilitate China market growth

	Product	Approval	Indication	Market
2020.09	Sodium Phenylbutyrate*	2021.05	Urea cycle disorders	Orphan disease medicine
2021.02	Donafenib	2021.06	Advanced liver cancer Thyroid cancer	2023 sales projected by research report : c. RMB 680 million
2021.06	Bimatoprost	2023.02	Glaucoma	Prostaglandin drug products c. RMB 1 billion
2022.11	Azilsartan	2022.09	Hypertension	c. RMB 100 million

* Customer's clinical trial for new indication in progress

- Changshu site expects to conduct more inspections in 2023



Financial Performance

Consolidated Income Statement

NTD Million except for EPS	1Q 2023		YoY	1Q 2022	
Revenue	648	100%	-12%	738	100%
Gross Profit	244	37%	-18%	298	40%
Operating Expenses	(195)	(30)	-7%	(209)	(28)
Operating Profit	49	7%	-45%	88	12%
Net Profit before Tax	53	8%	-45%	97	13%
Net Profit after Tax	42	6%	-46%	77	10%
EPS (NTD)	0.05	-	-	0.10	-

Sales Distribution – By Business





Unit: USD/M

	Generic API	CDMO	Drug Product
1Q 2023 Sales	17.0	2.1	2.2
YoY	-3.6%	-61.0%	-34.3%

Sales Distribution – By Indication





Unit: USD/M

	Oncology	CNS	Others
1Q 2023 Sales	14.9	4.5	1.9
YoY	-5.8%	-40.4%	-36.7%

Sales Distribution – By Region





Unit: USD/M

	US & Canada	EU	Japan	India	China	Others
1Q 2023 Sales	2.4	5.7	4.4	3.8	2.1	2.9
YoY	-48.9%	-17.2%	5.0%	-5.3%	-18.8%	-26.9%

Consolidated Balance Sheet

NTD Million	2023/03/31		2022/03/31	
Cash and Cash Equivalents	4,434	37%	4,166	35%
Accounts Receivable	406	3%	449	4%
Inventories	1,403	12%	1,299	11%
Property, Plant & Equipment	3,761	31%	4,043	34%
Other Current/Non-Current Assets	1,967	17%	1,984	16%
Total Assets	**11,971**	**100%**	**11,941**	**100%**
Financial Debt	90	1%	17	0%
Other Current Liabilities	787	7%	611	5%
Other Non-Current Liabilities	636	5%	673	6%
Total Liabilities	**1,513**	**13%**	**1,301**	**11%**
Total Shareholders' Equities	**10,458**	**87%**	**10,640**	**89%**

Consolidated Cash Flow Statement

NTD million	1Q 2023	1Q 2022	Dif.
From Operating Activities	**197**	**135**	**62**
Depreciation & Amortization	116	95	21
From Investing Activities	**(66)**	**(79)**	**13**
Capital Expenditure	(66)	(77)	11
From Financing Activities	**10**	**16**	**(6)**
Effect of foreign exchange rate changes	**(2)**	**13**	**(15)**
Net Change in Cash	**139**	**85**	**54**
Beginning Balance	**4,295**	**4,081**	**214**
Ending Balance	**4,434**	**4,166**	**268**



Q & A

Brand Quality with Asian Advantages

www.scinopharm.com

1789 TT